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Abstract
Background: Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has
also shown antiviral efficacy in antiretroviral-naı¨ve patients. However, data on the switching from protease inhibitors (PI) to
ETR are lacking.
Methods: HIV-1-infected patients with suppressed viral load (VL) during a PI-containing regimen (.12 months) and no
previous virological failure were randomized to switch from the PI to ETR (400 mg/day, dissolved in water) (ETR group,
n = 22) or to continue with the same regimen (control group, n = 21). Percentage of patients with VL#50 copies/mL were
assessed at week 48, as well as changes in CD4 T-cell counts and metabolic profile.
Results: We included 43 patients [72.9% male, 46.3 (42.2; 50.6) years]. Two patients receiving ETR (grade-1 diarrhea and
voluntary discontinuation) and another in the control group (simplification) discontinued therapy early. No patients
presented virological failure (two consecutive VL.50 copies/mL); treatment was successful in 95.2% of the control group
and 90.9% of the ETR group (intention-to-treat analysis, missing = failure) (p = 0.58). CD4+ T-cell counts did not significantly
vary [+49 cells/mL in the ETR group (p = 0.25) and 24 cells/mL in the control group (p = 0.71)]. The ETR group showed
significant reductions in cholesterol (p,0.001), triglycerides (p =,0.001), and glycemia (p = 0.03) and higher satisfaction (0–
10 scale) (p = 0.04). Trough plasma concentrations of ETR were similar to observed in studies using ETR twice daily.
Conclusion: Switch from a PI-based regimen to a once-daily combination based on ETR maintained undetectable VL during
48 weeks in virologically suppressed HIV-infected patients while lipid profile and patient satisfaction improved significantly.
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Introduction
Etravirine is a second-generation non-nucleoside analog reverse
transcriptase inhibitor (NNRTI). It was approved by the U.S.
Food and Drug Administration and the European Medicines
Agency in 2008 for clinical use in adults with incomplete virologic
suppression and resistance to multiple antiretroviral agents,
including previous NNRTI, in combination with a ritonavir-
boosted protease inhihitor (PI) [1–3].
The clinical recommendation for market authorization of
etravirine was mainly based on the results of 2 pivotal phase 3
studies, DUET-1 and DUET-2 [4,5]. The etravirine-containing
arm showed higher rates of viral suppression than the placebo
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arm, and the likelihood of virologic failure was correlated with the
number of baseline NNRTI and nucleoside analog reverse
transcriptase inhibitor (NRTI) resistance mutations [4–9]. In
addition, patients taking etravirine, administered twice daily,
tolerated the regimen well, and the magnitude of the adverse
events observed during treatment suggests that etravirine has a
favorable safety and tolerability profile [4,5,10].
Since pharmacokinetic studies support the use of etravirine once
daily [11–14], it appears to be a suitable option in antiretroviral
simplification strategies. However, data on simplification with
etravirine are lacking, and only 2 recently published studies have
assessed switching from the NNRTI efavirenz to etravirine in
virologically suppressed patients [15,16]. Both studies showed the
etravirine-containing regimen to be well tolerated and reported a
significant improvement in efavirenz-related central nervous
system symptoms. Nevertheless, we do not know whether patients
with sustained undetectable HIV-1 RNA levels receiving a PI-
based regimen can safely switch their current PI to etravirine. As
nowadays antiretroviral treatment should be continued indefinite-
ly, different effective and safe options, other than PI-based
combinations, are required, mainly for those subjects suffering
PI- or ritonavir-related toxicities or reporting an uncomfortable
dosin Schedule with the regimen (twice daily dose, use of
ritonavir…).
We designed a pilot study to test the efficacy and safety of
switching from a PI to etravirine as an antiretroviral switching
strategy in patients with a suppressed viral load. Our approach was
based on the high antiviral potency and high genetic barrier to
resistance of etravirine, as well as the favorable safety profile and
patient-friendly dosing (once daily dose and dissolved in water).
Methods
Ethics Statement
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The study protocol was approved by the Ethics
Committee of our center ‘‘Germans Trias I Pujol Universitary
Hospital. Barcelona, Spain’’ and local health authorities (Dr J.
Costa, President of Clinical Research Ethics Committee), before
the trial began and was undertaken in accordance with the
Declaration of Helsinki and the requirements of Good Clinical
Practice. (ClinicalTrials.gov ISRCTN 01034917). Study Protocol
code: ETRA-SWITCH, Nu 2009-016455-21 Eudra CT, version 1
(September, 29/2009).
Written informed consent was obtained from all participants.
Study Design and Participants
We performed a 48-week, prospective, randomized, pilot study
in HIV-1-infected outpatients. The study candidates were all those
patients receiving standard triple-drug highly active antiretroviral
therapy (HAART) including a PI for more than 12 months, with
an undetectable viral load (VL ,50 copies/mL) for more than 6
months and no documented resistance to NNRTIs or NRTIs or
virological failure with previous regimens. For therapy to be
switched to etravirine, patients had to fulfill at least 1 of the
following criteria: dyslipidemia (low-density lipoprotein [LDL]
cholesterol .130 mg/dL or triglycerides .150 mg/dL, according
our reference laboratory, or current use of lipid-lowering agents),
antiretroviral-related gastrointestinal disturbances, or a repeatedly
expressed dissatisfaction with the current antiretroviral regimen.
Randomization, Follow-up, and Assessment
Participants were randomly assigned in a ratio of 1:1 to switch
from the PI to etravirine (400 mg/day, dissolved in water; ETR
group) or to continue with the same PI-based regimen (control
group). The treatment allocation list was generated by blocks using
numbers drawn from the uniform distribution.
Patients were assessed at week 0 (baseline) and weeks 4, 12, 24,
36 and 48. The laboratory data recorded at these time points
included plasma HIV-1 RNA, CD4 and CD8 T-cell counts,
biochemistry (fasting conditions) including a complete lipid profile
(total cholesterol, LDL cholesterol, high-density lipoprotein
cholesterol [HDL], triglycerides).
Virological failure was defined as the viral rebound (confirmed
viral load .50 copies/mL). HIV-RNA was determined using the
AMPLICOR HIV-1 MONITOR Test, v 1.5 (Roche Diagnostic,
Basel, Switzerland).
HIV-related data (time since HIV diagnosis, risk behavior,
nadir CD4 T-cell count, time on antiretroviral therapy, and time
on NNRTIs, NRTIs, and PIs) were recorded from the patient’s
records.
Adverse events and reasons for discontinuation were also
recorded at the same time points. Adverse events were classified
according to the definitions of the World Health Organization.
Reasons for discontinuation were classified as follows: virological
failure, adverse events (grade 1–2 or 3–4), death, or any other
cause (eg, voluntary discontinuation and simplification).
Patient satisfaction with therapy was assessed using two 0–10
Likert scales (satisfaction with treatment and preference for
treatment) at baseline and weeks 24 and 48.
Etravirine trough concentrations in plasma were also deter-
mined at week 12 in all patients who were receiving the drug.
Study Objectives and End Points
The principal efficacy analyses (proportion of patients who
maintained HIV-1 RNA #50 copies/ml at week 48) were
performed on-treatment and intention-to-treat (missing equal to
failure). Additionally, variations in CD4 and CD8 T-cell count at
each time point from baseline were also compared between
groups, as well as changes in metabolic parameters (lipid
metabolism and glucose) and liver enzimes. Changes in lipid
parameters after switching to etravirine were also evaluated
according to the PI used at baseline. Safety was assessed by
comparing the percentage of patients who discontinued the study
during the 48 weeks of follow-up and the percentage of patients
with serious adverse events (grade 3–4).
Patient satisfaction with treatment at weeks 24 and 48 was
compared between treatment arms and also by stratifying
participants according to the reason for switching at baseline.
Etravirine trough concentrations in plasma were described and
compared with historical data from studies including subjects
taking etravirine not dissolved in water.
Statistical Analyses
The analysis of the study included comparisons between
baseline and weeks 4, 12, 36 and 48 in each group and
comparisons between groups (control versus ETR group) at each
visit point.
Quantitative variables were expressed as the mean and standard
deviation (SD) or as the median and interquartile range (IQR);
qualitative variables were expressed as frequencies and percent-
ages. Normally distributed continuous variables were compared
using the t test; non-normally distributed variables were compared
using the Mann-Whitney test. The dependent t test for paired
samples or the Wilcoxon signed rank test was performed to assess
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the significance of changes observed over time. The chi-square test
or Fisher exact test was used as appropriate to compare discrete
variables.
Statistical analysis was performed with the SPSS 15.0 program
(SPSS, Inc., Chicago Illinois, USA).
Results
The study sample comprised 43 patients: 22 in the ETR group
and 21 in the control group.
Epidemiological, clinical, and HIV-related characteristics were
summarized in table 1. Overall, the median (IQR) age was 46.3
(42.2; 50.6) years and 72.9% of patients were male. The median
time (IQR) since diagnosis of HIV infection was 12 (5.8; 16.7)
years; the median time (IQR) on therapy and on PIs was 6.1 (3.5;
11.6) years and 4.9 (2.8; 8.18) years, respectively.
The main reasons for participating in the study were
dyslipidemia (48.8%), followed by low satisfaction with the
previous regimen (twice-daily dosing and need to store ritonavir
in a refrigerator) (39.5%) and gastrointestinal disorders (11.6%)
(Table 1). At baseline, most patients were taking atazanavir and
lopinavir/ritonavir based-regimen; the other PIs were fosampre-
navir and saquinavir (Table 1).
Virological and Immunological Outcome
The percentage of patients who maintained HIV-1 RNA #50
copies/ml at week 48 was similar between the groups, with no
significant differences; 100% of patients who completed the study
maintained HIV-RNA #50 copies/mL at week 48 in both
groups, respectively (p = 0.84) (on-treatment analysis). The pro-
portion in the intention-to-treat analysis (missing = failure) was
95.2% in the control group and 90.9% in the ETR group
(p = 0.96). Difference of proportions between groups with 95% CI
was 4.33(210.75; 19.40).
Mean (SD) CD4 T-cell counts in the ETR group increased from
702 (333) to 749 (345) cells/mL, although the difference did not
reach statistical significance (p = 0.25), and did not vary in the
control group [from 717 (232) to 713 (270) cells/mL; p = 0.81]. No
statistically significant differences were recorded between groups at
any time point (p = 0.71 at week 48).
Metabolic Changes
Patients from the ETR group showed significant reductions in
cholesterol (from 207 to 191 mg/dL, p,0.001), triglycerides (from
186 to 132 mg/dL, p,0.001), and glycemia (from 97 to 93 mg/
dL, p = 0.03) (Table 2). Differences between groups were recorded
for triglycerides (p = 0.04) and glycemia (p = 0.03) at week 24. At
week 48, no patients from the ETR group presented grade 3–4
elevations in total and LDL cholesterol while were recorded in
10.5% and 5.6%, respectively, of the control group; no differences
were seen between groups in any of both parameters (p = 0.23 and
p = 0.47, respectively). No patients showed grade 3–4 elevations in
triglyceride levels at week 48.
When patients were stratified according to the PI used at
baseline, a significant improvement was observed at week 48 in
total cholesterol, triglycerides, and glycemia in patients who
switched from lopinavir/ritonavir to etravirine (p = 0.01, p = 0.03,
and p,0.0001, respectively). A significant difference was also
Table 1. Baseline epidemiological and HIV-related characteristics.
ETR group (n =22) Control group (n=21)
Age, years 47.4 (42; 51) 46.2 (41.8; 50)
Gender, male (%) 63.6 76.2
Time since HIV diagnosis, years 12.9 (5.9; 17.3) 8.1 (4.2; 16.5)
Time on antiretroviral therapy, years 8.3 (3.9; 12.1) 8.1 (4.2; 16.5)
Time on PI, years 3.6 (0.7; 8.2) 5.2 (3.4; 9.6)
CD4 cell count/mL 729 (512; 858) 711 (484; 931)
Reason for change, n (%)
Dyslipemia 12 (54.5) 9 (42.9))
Gastrointestinal disturbances 3 (13.6) 2 (9.5)
Posology (BID)/RTV 7 (31.8) 10 (47.6)
Use of lipid-lowering agents (LLD) n% 4 (18.2) 2 (9.5)
NNRTI, n (%)
Abacavir+Lamivudine 8 (36.4) 7 (33.3)
Tenofovir+Emtricitabine 13 (59) 13 (61.9)
Others combinations 1 (4.6) 1 (4.8)
Baseline PI, n (%)
Atazanavir/RTV (n = 23) 11 (50.5) 12 (57.1)
Lopinavir/RTV (n = 11) 7 (31.8) 4 (19.0)
Fosamprenavir/RTV (n = 6) 3 (13.6) 3 (14.3)
Saquinavir/RTV (n = 3) 1 (4.5) 3 (9.5)
Darunavir/RTV (n = 0) 0 0
Hepatitis C/B virus, n (%) 3 (13.6) 4 (19)
Parameters are expressed as Median value (IQR 25;75) except when it was specified. HCV, hepatitis C virus; HBV, hepatitis B virus; PI, protease inhibitors; NNRTI, non-
nucleoside analog reverse transcriptase inhibitor; RTV, ritonavir; BID, twice daily dosin.
doi:10.1371/journal.pone.0084676.t001
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observed in triglycerides in patients who switched from atazanavir
(p = 0.04) and in glycemia in those who switched from fosampre-
navir (p = 0.04).
When patients were stratified according to the presence of
dyslipidemia or not at baseline, no difference were seen in lipid
parameters (total cholesterol, p = 0.48; HDL-cholesterol, p = 0.44;
LDL-cholesterol, p = 0.54; triglycerides, p = 0.54).
Safety and Satisfaction
Therapy was discontinued early by 2 patients receiving
etravirine (1 case of diarrhea (grade 1) and 1 voluntary discontin-
uation) and in 1 patient in the control group (change of regimen to
simplify). No serious clinical adverse events (grade 3–4) were
reported during the study.
No significant changes in liver enzymes were observed in either
group, and no grade 3–4 elevations were recorded. No differences
were seen between the groups at week 48 (aspartate aminotrans-
ferase, p = 0.77; alanine aminotransferase, p = 0.13).
Mean (SD) patient satisfaction rose from 7.7 (1.4) at baseline to
8.9 (1.3) at week 24 and 9.2 (1.4) at week 48 in the ETR group;
these values decreased slightly in control patients from 6.0 (2.3) to
5.6 (2.4) and 5.3 (2.1), respectively (Table 2). Differences between
groups were seen at weeks 24 (p = 0.001) and 48 (p = 0.04). These
differences were marked when the subgroup of patients who
switched regimen because of gastrointestinal disorders was
analyzed: those who changed to etravirine reported higher
satisfaction at weeks 24 and 48 than those who did not (p = 0.01
and 0.01, respectively).
The mean (range) etravirine trough concentrations in plasma
was 569.3 (202–1141) ng/mL. Interpatient variability (% coeffi-
cient of variation) in etravirine concentrations was 50.5%.
Discussion
Etravirine-based regimens could prove to be an excellent
switching strategy in virologically suppressed HIV-infected
patients thanks to their safety profile and patient-friendly dosing.
Nonetheless, data on etravirine in this scenario are scarce.
At the end of the 1990s, many studies compared the antiviral
outcome of an NNRTI (nevirapine or efavirenz) with the PIs used
at the time [17–22]. Briefly, NNRTIs were non-inferior (in terms
of antiviral potency) to PIs used in simplification strategies.
Additionally, the lipid profile improved in most patients, especially
with nevirapine [17–22]. Etravirine is a commercialized NNRTI
that was approved to treat patients with incomplete virological
suppression and resistance to previous NNRTI [4,5]. Published
evidence also shows that etravirine works well as first-line HIV
therapy, as part of a once daily regimen, compared with efavirenz
[23,24]. This new-generation NNRTI induces few neuropsychi-
atric side effects and has a friendly lipid profile [23–25].
Nonetheless, despite its good safety profile, no experience has
been reported with etravirine as an alternative therapy for
simplification in virologically suppressed HIV-infected patients
taking a ritonavir-boosted PI. The main reasons for switching from
PIs in the clinical practice include PI-related laboratory toxicity
(mainly metabolic abnormalities), clinical disorders (mainly gas-
trointestinal), and dosing-related conditions. In our study, the
main reasons for switching were dyslipemia (almost half of all
patients) and low satisfaction with the previous regimen (twice-
daily dosing and the need to store ritonavir in a refrigerator)
(around 40%). The low rate of patients who switched because of
gastrointestinal disorders (11.6%) indicates that current regimens
are generally well tolerated. The most frequently switched PI was
atazanavir/ritonavir (56%), since, at the initiation of the study,
ritonavir had to be kept in a refrigerator (a complaint from many
patients).
Although this is a pilot study, our results revel that the switch
from a PI to etravirine maintains virological suppression after 48
weeks of follow-up. No patients experienced viral rebound in
either treatment arm. Moreover, CD4 T-cell counts increased
slightly in patients who switched to etravirine. Although this
increase was not statistically significant, it could be clinically
relevant in some patients, especially in those with low CD4 T-cell
counts.
As expected, and consistent with previous data for the effect of
etravirine on lipid profile [4,5,23–25], the switch from a PI to
etravirine led to an improvement in metabolic parameters. After
48 weeks, a significantly more favorable metabolic profile
(decreased levels of total cholesterol, triglycerides, glycemia and
no patients with grade 3–4 dyslipidemia at week 48) was observed
in patients who switched to etravirine than in those who continued
with a ritonavir-boosted PI. This improvement in metabolic
parameters, including glycemia, was specially observed in those
patients who switch to etravirine because of dyslipidemia, and
Table 2. Changes in lipid profile and glycemia and satisfaction.
ETR group P value* Control group P value*
Baseline (n =22)
Week 24
(n =20 )
Week 48
(n=20)
Baseline
(n=21)
Week 24
(n=20 )
Week 48
(n=20)
Total cholesterol (mg/dL) 207.2 (42.8) 186 (41) 190.8 (39.8) ,0.001 197.8 (47.4) 204.4 (42.9 199 (49.6) 0.71
HDL-cholesterol (mg/dL) 52.9 (18.3) 48 (14.5) 52.8 (20.4) 0.88 54.2 (19.6) 52.3 (21) 55.1 (24.9) 0.59
CT/HDL-cholesterol ratio 3.96 3.85 3.57 0.12 3.86 4.19 3.78 0.82
LDL-cholesterol (mg/dL) 116.6 (38.9) 113 (33) 110.5 (32.2) 0.10 114.6 (43.8) 121 (38.3) 113.6 (35.4) 0.50
Triglycerides (mg/dL) 186.4 (95.8) 119.4 (56) 132.4 (79.3) ,0.001 145.7 (106.4) 157 (9) 116.1 (58.5) 0.14
Glycemia (mg/dL) 97.4 (11.3) 94 (15) 92.7 (11.7) 0.03 90.3 (10.4) 88 (7.4) 88.0 (8.3) 0.22
Satisfaction** 7.7 (1.4) 8.9 (1.3) 9.2 (1.4) ,0.01 6 (2.3) 5.6 (2.4) 5.3 (2.1) 0.21
All values are shown as mean (SD).
*P values express intra-group differences between baseline and week 48.
Between groups, the only differences recorded were for triglycerides (p = 0.04) and glycemia (p = 0.03) at week 24.
HDL, High density lipoprotein; LDL, Low density lipoprotein.
**Patient satisfaction was assessed using two 0–10 likert scales.
doi:10.1371/journal.pone.0084676.t002
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especially marked in those patients who switched from lopinavir/
ritonavir. Therefore, a favorable lipid profile is likely to reflect a
class-wide association [26–32]. However, no improvement in
HDL-cholesterol levels was observed in our participants after
switching, a finding that is consistent with those of other studies on
etravirine [25], but contrary to those observed with the other 2
NNRTIs, efavirenz and, mainly, nevirapine [26–32].
As for safety, the low rates of early withdrawal in the ETR arm
that were similar to those in the control group support previous
data on the good tolerability and low toxicity of etravirine
[4,5,15,16,23,24]; in fact, treatment failed in an even lower
percentage of patients in our study than in others [15]. Only 1
patient interrupted the study prematurely because of toxicity
(grade 1 diarrhea), which eventually did not seem to be associated
with etravirine. A further 2 patients (1 in each arm) interrupted the
study for other reasons (simplification and voluntary discontinu-
ation). No grade 3–4 drug-related adverse events were reported in
any patient receiving etravirine. As well, no significant increases in
liver enzymes were recorded with the use of etravirine, even in
patients with hepatitis C or B coinfection.
As patient satisfaction is generally high with current antiretro-
viral combinations, it is usually difficult to demonstrate differences
after a switch. Among our patients, however, satisfaction improved
significantly after switching to etravirine (even though the
subgroup of patients evaluated was small), specifically in those
with gastrointestinal disturbances at baseline. Nonetheless, some
patients did not consider 4 tablets of etravirina (used in the study)
plus the rest of the nucleoside backbone a simplified regimen.
Marketing of 200-mg etravirine tablets has recently been approved
in North America and in Europe. This new formulation will
facilitate dosing and, consequently, patient acceptance and
satisfaction. In addition, plasma concentrations of etravirine,
administered once daily dissolved in water, were in the same range
to those observed in subjects receiving undispersed etravirine
tablets [11–14]. As well, all patients showed etravirine concentra-
tions above the protein-binding adjusted 50% effective concen-
tration 4 ng/mL. This data support the safety use of once daily
dosing for etravirine, and the possibility of dispersing the tablets in
order to enhance treatment convenience.
The limited sample size of the study does not permit to strongly
state our conclusions but this pilot study provides initial data about
the use of an etravirine-based regimen as a possible strategy in
subjects with PI-associated toxicities or dissatisfied with their
regimens. Additionally, this exploratory study allows us to establish
guidelines for future studies with more patients. The randomized
and controlled study designs, however, are both strengths of the
study that becomes our results in useful information.
In conclusion, this randomized trial seems to demonstrate the
maintenance of antiviral efficacy 48 weeks after switching from a
PI to etravirine. Our results also confirm the favorable safety
profile of etravirine, which has a lipid-friendly profile that is similar
to that of the other commercialized NNRTIs and better than that
of PI-containing regimens. Consequently, etravirine could be
considered as an alternative in virologically suppressed HIV-
infected patients receiving a PI-based antiretroviral combination
and who have not experienced failure with other NNRTI-based
regimens, mainly in those with metabolic disturbances.
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